Palmitic Acid and Human Microvascular Function
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Quercetin (dietary supplement), Placebo.
- Who it may be relevant to
- Registry conditions: Microvascular Dysfunction, Microvasculature, Cardiovascular Diseases, Cardiovascular Diseases (CVD). Basic parameters: 18 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Use of Quercetin to Increase Resiliency to Palmitic Acid in the Human Microvasculature
Overview
The goal of this study is to learn how a supplement Quercetin can affect microvascular function. Participants will: * give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.
Interventions
- Dietary supplement Quercetin (dietary supplement)
Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function. - Drug Placebo
Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
Primary outcome measures
- Change in blood vessel dilation [Time frame: 2 hours]
Secondary outcome measures (1)
- Change in Perfused Vessel Density [Time frame: 0.5 hours]
Eligibility criteria
Inclusion criteria
- Obesity (BMI>30)
- Aged 18-40 years
- English Speaking
Exclusion criteria
- BMI>60
- Resting SBP ≥180 mmHg or DBP ≥ 110mmHg
- Pregnancy or breastfeeding.
- Prior history of myocardial infarction
- Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)
- Active mouth sores that affect the buccal mucosa.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Basic science
Study locations
United States · 1 center
- Froedtert Hospital — Wauwatosa
Identifiers
NCT: NCT06683534 · PRO00053081